Specifically, the zinc oxide NPs activity has been reported against HepG2 (liver cancer) and MCF-7 (breast cancer) cells in a dose-dependent manner, being able to lower the levels of apoptotic markers p53, Bax, Bcl-2, and caspase-3. The gene discussed is TP53; the disease is breast cancer.